We studied the incidence among, risk factors for, and survival of adult patients with acute leukemia and hepatosplenic candidiasis during the period 1980 to 1993. Of 562 adult patients with acute leukemia, 38 (6.8%) had hepatosplenic candidiasis. The incidence of infection increased fivefold during the study period. The incidence was higher among patients with acute lymphatic leukemia (11.3%) than among those with acute myeloid leukemia (5.1%) (P = .01). The median survival was 9.5 months, and by the end of follow-up, 74% of patients had died. Patients whose leukemia was in remission before the last cytotoxic treatment preceding hepatosplenic candidiasis survived longer than did patients with newly diagnosed or refractory or relapsed leukemia (P = .0065). Eleven patients died within 3 months after the diagnosis of the infection: 7 of 16 with newly diagnosed leukemia, 4 of 10 with refractory or relapsed leukemia, and 0 of 12 with leukemia in remission (P = .028). In all of the patients who died within 3 months, infection was found at autopsy. In conclusion, the incidence of hepatosplenic candidiasis has significantly increased since 1980, and the outcome for patients with this infection is related to the stage of leukemia.
Hepatosplenic candidiasis was recognized as a distinct form of invasive candidiasis in patients with acute leukemia in the early 1980s [1] . The incidence of this form of candidiasis seems to have increased [2] [3] [4] [5] . Although hepatosplenic candidiasis is recognized as a major problem in the treatment of acute leukemia, there are little data on its incidence among patients with leukemia [4] . This paucity of information may be due to difficulties in confirming the specific diagnosis [6] .
The mortality due to hepatosplenic candidiasis in patients with leukemia is significant [1, 2, 7, 8] . In most published reports, diagnoses have been based on autopsy findings or there were only a few cases [1, 2, 5, 7, 9, 10] . Little is known about the impact of this infection on patient survival. In a tertiary care hospital, we investigated the incidence among, risk factors for, and survival of adult patients with acute leukemia and hepatosplenic candidiasis over a period of 14 years.
Patients and Methods
During the period 1980-1993, 562 patients with acute leukemia were treated at the Department of Medicine, Helsinki University Central Hospital, Helsinki. Reports on fungal cultures, pathological examinations of specimens, and autopsies of patients with acute leukemia were screened to find patients with hepatosplenic candidiasis.
Treatment of Acute Myeloid Leukemia (AML)
The intensity of induction therapy was similar throughout the whole study period [11, 12] . The treatment cycles consisted of cytarabine and thioguanine for 7 to 10 days and daunorubicin or idarubicin for 3 days. Cycles of consolidation therapy were of low intensity until 1984, and they seldom induced severe long-lasting neutropenia [11] . In later protocols, postremission therapeutic courses were at least as intensive as induction therapy, and all of them induced severe neutropenia for 2 to 4 weeks [12] .
Treatment of Acute Lymphatic Leukemia (ALL)
Until June 1986, induction therapy consisted of weekly administrations of doxorubicin and vincristine, prednisone for 4 weeks, and asparaginase for 10 days [13] . In 1984, cyclophosphamide was added to this therapy [14] . The intensity of consolidation and maintenance treatments was low. In 1986, more intensive induction and consolidation therapies were commenced [15] . High doses of cytarabine, etoposide, and teniposide were introduced, the infusion time of methotrexate was increased from 4 to 24 hours, and high doses of dexamethasone were given instead of prednisone. In the protocol used during the years 1987-1990, therapies induced severe stomatitis and gastrointestinal toxic effects [15] .
Prophylactic Antimicrobial Regimens
No systemic or topical antibacterial or antifungal treatment was used as prophylaxis during the study period.
Definition of Hepatosplenic Candidiasis
A patient was considered to have hepatosplenic candidiasis if (1) focal lesions in the liver, spleen, or kidneys were found by imaging methods or at autopsy and (2) a specific diagnosis of yeast infection was established either by the culture of blood or a deep-tissue specimen or by appropriate findings of microscopy of a deep-tissue specimen that was stained according to standard laboratory staining methods. Patients for whom Candida was isolated from blood but who had no evidence of deep-organ involvement were not included in the study.
Imaging Methods
CT and ultrasonography were used for imaging of visceral organs throughout the study period. Since December 1990, MRI was used systematically for imaging of livers of all patients for whom hepatic candidiasis was clinically suspected [16] .
Statistical Analysis
The x2 test was used for comparison of differences in rates.
An estimation of the probability of survival was made according to the Kaplan-Meier method. Comparisons of the survival between patient groups were assessed with logrank statistics with use of BMDP statistical software (BMDP, West Los Angeles). P values of <.05 were regarded as statistically significant.
Results
Of the 562 patients with leukemia (411 with AML and 151 with ALL) who were treated during the 14-year study period, 38 (6.8%) had hepatosplenic candidiasis. The mean age of these patients was 46 years (range, 17-65 years). There were 20 males and 18 females. Twenty-one patients had AML, and 17 had ALL. The states of the leukemias before the last cytotoxic treatment preceding the diagnosis of hepatosplenic candidiasis were as follows: newly diagnosed disease, 16 patients; remission, 12; and refractory or relapsed disease, 10. The median duration of the last episode of neutropenia (defined as a blood neutrophil count of X 10 9/L) before the diagnosis of hepatosplenic candidiasis was 19 days (range, 8-45 days).
Focal lesions were seen in the following visceral organs: liver alone, 21 patients; spleen alone, 1; spleen and liver, 6; liver, kidneys, and spleen, 4; liver and kidneys, 2; and spleen and kidneys, 3. One patient had a combination of an exceedingly high alkaline phosphatase level and focal lesions in the kidneys and pancreas. In 13 of these patients, lesions also were seen outside the abdominal or retroperitoneal cavities.
Cultures of specimens from a total of 17 patients (45%; blood specimens, six patients; deep-tissue samples, 11 patients) yielded Candida (table 1) . In addition, yeast structures were detected by microscopic examination of visceral-organ samples from 14 of these 17 patients. In a further 21 cases, the specific diagnosis was based on microscopic findings of yeast structures in visceral-organ samples. For 11 (29%) of 38 patients, the diagnosis of hepatosplenic candidiasis was made only at autopsy; cultures of blood specimens from three of these patients yielded Candida shortly before death.
Before the detection of hepatosplenic candidiasis, 35 patients received systemic empirical antifungal treatment. Only one of the 38 patients did not receive systemic antifungal treatment either before or after the diagnosis of the infection (table 1) . The mean total dose of amphotericin B was 1,654 mg (range, 0-7,230 mg). Three patients did not receive treatment with amphotericin B: two received miconazole, and one received ketoconazole followed by flucytosine. Legionella antigen was detected in bronchoalveolar lavage fluid from a patient with pneumonia who did not receive antifungal treatment, but hepatosplenic candidiasis was confirmed at autopsy.
The incidence of hepatosplenic candidiasis in patients with acute leukemia increased significantly: between 1980 and 1984, there were 4 cases (1.9%) in 213 patients; between 1985 and 1988, 17 cases (9.9%) in 171 patients; and between 1989 and 1993, 17 cases (9.6%) in 178 patients (P = .002; x2 test).
The annual incidence of hepatosplenic candidiasis is shown in table 2. The incidence of hepatosplenic candidiasis was significantly higher among patients with ALL than among those with AML (11.3% vs. 5.1%, respectively) (P = .01; x2 test).
The incidence of hepatosplenic candidiasis increased significantly among patients with both types of acute leukemia: between 1980 and 1984, 3 cases (1.8%) in 165 patients with AML and 1 case (2.1%) in 48 patients with ALL; between 1985 and 1988, 11 cases (8.8%) in 125 patients with AML and 6 cases (13%) in 46 patients with ALL; and between 1989 and 1993, 7 cases (5.8%) in 121 patients with AML and 10 cases (17.5%) in 57 patients with ALL (P = .03 for AML and P = .04 for ALL; x2 test).
By April 1995, of the 38 patients with hepatosplenic candidiasis, 28 (74%) had died, and 10 (26%) were alive. The median survival from diagnosis of yeast infection for all patients was 9.5 months ( figure 1A ). Logrank analysis showed that those patients whose leukemia was in remission when hepatosplenic candidiasis manifested survived longer than did those with newly diagnosed or refractory or relapsed leukemia (P = .0065) (figure 1B). Logrank analysis of sex, type of leukemia (AML vs. ALL), age (50 years of age or younger vs. older than 50 years of age), duration of last episode of neutropenia (-20 days vs. >20 days), and year of infection (1980-1987 vs. 1988-1993) identified no other variables of prognostic significance. Eleven patients died within 3 months after the diagnosis of hepatosplenic candidiasis (table 1) . In all of these patients, the infection was also evident at autopsy. Rates of short-term mortality due to infection were lower among younger patients (50 years of age or younger) and those whose leukemia was in remission when hepatosplenic candidiasis manifested than among patients with newly diagnosed or refractory or relapsed leukemia (table 3) . Another 10 patients with hepatosplenic candidiasis died between >3 and < 12 months after the diagnosis of the infection. At autopsy, infection was still evident in two but not in five of these patients. Autopsies were not performed on three patients with previously diagnosed hepatosplenic candidiasis. One year after the diagnosis of hepatosplenic candidiasis, only two of the 12 patients with leukemia in remission had died, whereas 11 of the 16 patients with newly diagnosed leukemia and eight of the 10 patients with refractory or relapsed leukemia had died (P = .03; x2 test).
Cytotoxic treatment was given to 23 patients after the diagnosis of hepatosplenic candidiasis. The median delay of cytotoxic treatment due to the infection, calculated as the time from the detection of hepatosplenic candidiasis until the next cytotoxic treatment, was 73 days (range, 13-160 days). None of these patients had reactivation of infection. Twenty of these 23 patients received systemic antifungal treatment during episodes of neutropenia. Three patients later underwent allogeneic bone marrow transplantation and did not have any fungal infections.
Discussion
Our study of 562 adult patients with acute leukemia indicated a significant increase in the incidence of hepatosplenic candidiasis between 1980 and 1993. The mortality rate among patients with acute leukemia and hepatosplenic candidiasis was high, although only part of the deaths were directly attributable to the infection. Hepatosplenic candidiasis is difficult to diagnose. Cultures of blood and tissue samples often remain negative [6, 7] . A strong inflammatory reaction appears around the fungal organism after the recovery of neutrophils, and the number of fungal organisms inside the foci may be small. Although imaging methods reveal typical foci in the liver or spleen, in many cases both cultures and microscopic examinations of biopsy specimens remain negative for fungi [16] .
The new more-sensitive imaging methods such as MRI can detect foci in the liver of patients for whom hepatosplenic candidiasis is clinically suspected more frequently than CT or ultrasonography [16] . Ultrasonography often cannot detect foci, thus preventing directed invasive procedures. For some patients, invasive procedures must be avoided because of the risk of bleeding.
In this study, we included only patients with microbiologically or microscopically proven hepatosplenic yeast infection. Therefore, the incidence of hepatosplenic candidiasis in our study can be considered the minimum estimate of the true incidence of hepatosplenic candidiasis in this patient population. MRI was introduced systematically in 1990. Since a significantly increased incidence was already seen during the preceding period of 1985 to 1988, the increase is not explained by the introduction of a more sensitive imaging method.
Fungal infections have become more common as cytotoxic treatment of leukemia has become more intensive [4, 5] . At our hospital, the incidence of hepatosplenic candidiasis increased over fivefold during the study period. We found that the incidence of hepatosplenic candidiasis in patients with ALL was significantly higher than that in patients with AML. Antileukemic therapy plays an important role in the risk of invasive fungal infection [4] . It seems plausible to suggest that the increased intensity of our treatment protocols for ALL, including high doses of steroid components, could be the major factor influencing the dissemination of Candida [15] .
There is little information about the outcome for patients with hepatosplenic candidiasis [1, 8] . In most previous studies, diagnoses were based on autopsy findings, the study population was not always homogeneous, and the type of fungal infection varied [1] [2] [3] . To avoid these confounding factors, we focused only on patients with acute leukemia who were at high risk of contracting this infection.
We studied the survival of patients with acute leukemia and hepatosplenic yeast infection between 1980 and 1993. All patients whose fungal infections were diagnosed while they were alive received systemic antifungal treatment (90% received intravenous amphotericin B). Despite the antifungal treatment, the short-term mortality rate at 3 months after the diagnosis of the infection was almost 30% and was strongly dependent on the stage of leukemia when the infection manifested; none of the patients whose leukemia was in remission died within 3 months after the diagnosis of the infection, whereas almost one-half of the patients with newly diagnosed leukemia and over one-half of the patients with refractory or relapsed leukemia had died.
In all 11 patients who died within 3 months after the diagnosis of hepatosplenic candidiasis, the infection was the major cause of death. The treatment of hepatosplenic candidiasis often delays the treatment of leukemia, thereby exposing the patients to an increased risk of relapse. For those 23 patients who subsequently received cytotoxic therapy, the median delay of cytotoxic treatment caused by the infection was >2 months. In this retrospective study, it was difficult to assess exactly the effect of hepatosplenic candidiasis on long-term mortality. It seems that the infection can usually be successfully treated if the leukemia itself is in control, evidenced by the fact that 80% of the patients who had the infection when leukemia was in remission were alive 1 year after the infection was diagnosed.
In conclusion, the incidence of hepatosplenic candidiasis in patients with acute leukemia has significantly increased since the early 1980s. The survival of patients with acute leukemia and hepatosplenic candidiasis is related to the stage of leukemia. The short-and long-term mortality rates among patients whose leukemia was in remission when they contracted the infection were significantly lower than those among other patients. To improve the prognosis of patients with acute leukemia and hepatosplenic candidiasis, more effective prophylactic and therapeutic antifungal treatments are needed.
